SCHEMBL17809669

SCHEMBL17809669

CN1CCCc2cc(-c3ccc(C4CC4)nc3)c(C#N)cc21

nearest known ligand 0.40

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
RET P07949 7/20 0.40
USP30 Q70CQ3 1/20 0.39
KDM1A O60341 1/20 0.38
CYP11B2 P19099 2/20 0.38
KDM4E B2RXH2 1/20 0.38
ALDH1A1 P00352 1/20 0.38
GLA P06280 1/20 0.38
GAA P10253 1/20 0.38
HPGD P15428 1/20 0.38
CASP1 P29466 1/20 0.38
HSD17B10 Q99714 1/20 0.38
GPR119 Q8TDV5 1/20 0.37
LRRK2 Q5S007 1/20 0.37
SYK P43405 1/20 0.36
WDR5 P61964 1/20 0.35
MTOR P42345 1/20 0.35
CYP11B1 P15538 1/20 0.35
MAP3K5 Q99683 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17806344 0.86 GPR119 (0.40) RETUSP30KDM1ACYP11B2GPR119
SCHEMBL17809673 0.84 CYP11B2 (0.41) RETUSP30CYP11B2KDM4EALDH1A1
SCHEMBL17809654 0.84 CYP11B2 (0.41) RETUSP30KDM1ACYP11B2KDM4E
SCHEMBL17809653 0.81 USP30 (0.40) RETUSP30KDM1ACYP11B2HPGD
SCHEMBL17809792 0.81 CYP11B2 (0.39) USP30CYP11B2KDM4EALDH1A1GLA
SCHEMBL17809596 0.78 CREBBP (0.43) USP30KDM1ACYP11B2
SCHEMBL17809677 0.78 CYP11B2 (0.41) CYP11B2HPGDCASP1HSD17B10SYK
SCHEMBL17809672 0.77 CYP11B2 (0.45) CYP11B2ALDH1A1HSD17B10CYP11B1
SCHEMBL17809650 0.77 ALDH1A1 (0.41) USP30CYP11B2KDM4EALDH1A1GLA
SCHEMBL17809667 0.77 KDM4E (0.41) USP30CYP11B2KDM4EALDH1A1GLA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3224258-B1 4,5,6,7-TETRAHYDRO-1H-PYRAZOLO[4,3-C]PYRIDIN-3-AMINE COMPOUNDS AS CBP AND/OR EP300 INHIBITORS GENENTECH INC (US) 2019-08-14 EP disclosed
US-20170333406-A1 THERAPEUTIC COMPOUNDS AND USES THEREOF GENENTECH, INC. (US) 2017-11-23 US disclosed
US-9763922-B2 Therapeutic compounds and uses thereof GENENTECH, INC. (US) 2017-09-19 US disclosed
US-20160158207-A1 THERAPEUTIC COMPOUNDS AND USES THEREOF GENENTECH, INC. (US) 2016-06-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170333406-A1 THERAPEUTIC COMPOUNDS AND USES THEREOF EP300, HDAC1, HDAC10 RET 855/4885USP30 2156/4885KDM1A 307/4885
US-20160158207-A1 THERAPEUTIC COMPOUNDS AND USES THEREOF EP300, HDAC1, HDAC10 RET 855/4885USP30 2156/4885KDM1A 307/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.